Table 4.

Immune-related adverse events (irAEs) from adjuvant anti-PD-1 therapy in patients with resected melanoma.

	Any Grade	Grade 3–4
	N (%)	N (%)
-  No toxicity	135 (55%)	218 (89%)
-  Any toxicity	110 (45%)	27 (11%)
Toxicity *
-  Cutaneous toxicity	76 (31%)	1 (<1%)
-  Hypothyroidism	12 (5%)	0
-  Colitis	10 (4%)	4 (2%)
-  Arthritis	9 (4%)	1 (<1%)
-  Hepatic toxicity	8 (3%)	7 (3%)
-  Pneumonitis	8 (3%)	2 (1%)
-  Nephritis	4 (2%)	3 (1%)
-  Hypophysitis	1 (<1%)	1 (<1%)
-  Pancreatic toxicity	1 (<1%)	1 (<1%)
-  Adrenal insufficiency	1 (<1%)	1 (<1%)
-  Gastritis	1 (<1%)	1 (<1%)
-  Myositis	1 (<1%)	1 (<1%)
-  Myocarditis	1 (<1%)	1 (<1%)
-  Myelitis	1 (<1%)	1 (<1%)

* Patients may have more than one toxicity. N: number of patients.